Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:


Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Napabucasin

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Napabucasin?

Napabucasin is an investigational drug.

There have been 19 clinical trials for Napabucasin. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2016.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Pancreatic Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Boston Biomedical, Inc, 1Globe Biomedical Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd.

There are eighteen US patents protecting this investigational drug and one hundred and eighty-nine international patents.

Recent Clinical Trials for Napabucasin
A Study of Napabucasin(GB201) in Combination With Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer1Globe Biomedical Co., Ltd.Phase 3
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal CancerAustralasian Gastro-Intestinal Trials GroupPhase 2
A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male SubjectsBoston Biomedical, IncPhase 1

See all Napabucasin clinical trials

Clinical Trial Summary for Napabucasin

Top disease conditions for Napabucasin
Top clinical trial sponsors for Napabucasin

See all Napabucasin clinical trials

US Patents for Napabucasin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Napabucasin   Start Trial Anticancer agent Kyoto Pharmaceutical Industries, Ltd. (Kyoto, JP) Sumitomo Dainippon Pharma Co., Ltd. (Osaka, JP)   Start Trial
Napabucasin   Start Trial 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof Boston Biomedical, Inc. (Cambridge, MA)   Start Trial
Napabucasin   Start Trial Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer BOSTON BIOMEDICAL, INC. (Cambridge, MA) SUMITOMO DAINIPPON PHARMA CO., LTD. (Osaka-shi, Osaka, JP)   Start Trial
Napabucasin   Start Trial Method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione SUMITOMO DAINIPPON PHARMA CO., LTD. (Osaka, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Napabucasin

Drugname Country Document Number Estimated Expiration Related US Patent
Napabucasin Australia 2015272560 2034-06-09   Start Trial
Napabucasin Canada 2951627 2034-06-09   Start Trial
Napabucasin European Patent Office 3153508 2034-06-09   Start Trial
Napabucasin Japan 6549115 2034-06-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.